News
Lilly's Cyramza hits mark in first-line lung cancer trial
Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings w
